Monopar Therapeutics, Inc. (MNPR)
113.17
-1.21
(-1.06%)
USD |
NASDAQ |
Sep 09, 15:46
Monopar Therapeutics Shareholders Equity (Quarterly) : 130.86M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 130.86M |
| March 31, 2026 | 135.39M |
| December 31, 2025 | 137.83M |
| September 30, 2025 | 141.56M |
| June 30, 2025 | 52.20M |
| March 31, 2025 | 53.59M |
| December 31, 2024 | 55.04M |
| September 30, 2024 | 4.947M |
| June 30, 2024 | 6.090M |
| March 31, 2024 | 7.477M |
| December 31, 2023 | 5.588M |
| September 30, 2023 | 6.611M |
| June 30, 2023 | 7.837M |
| March 31, 2023 | 8.945M |
| December 31, 2022 | 10.09M |
| September 30, 2022 | 12.51M |
| June 30, 2022 | 14.52M |
| March 31, 2022 | 16.97M |
| December 31, 2021 | 18.94M |
| September 30, 2021 | 21.28M |
| Date | Value |
|---|---|
| June 30, 2021 | 23.35M |
| March 31, 2021 | 25.10M |
| December 31, 2020 | 15.69M |
| September 30, 2020 | 17.49M |
| June 30, 2020 | 12.15M |
| March 31, 2020 | 12.40M |
| December 31, 2019 | 12.63M |
| September 30, 2019 | 4.625M |
| June 30, 2019 | 5.127M |
| March 31, 2019 | 5.774M |
| December 31, 2018 | 6.918M |
| September 30, 2018 | 7.576M |
| June 30, 2018 | 8.124M |
| March 31, 2018 | 8.858M |
| December 31, 2017 | 9.619M |
| September 30, 2017 | 10.26M |
| June 30, 2017 | 4.090M |
| March 31, 2017 | 9.619M |
| December 31, 2016 | 2.831M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 134.98M |
| Total Liabilities (Quarterly) | 4.124M |
| Debt to Equity Ratio | 0.0008 |
| Current Ratio | 33.56 |
| Net Debt Paydown Yield | 0.00% |